Press releases
- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
- Actym Therapeutics Appoints Thomas Smart as CEO
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
- Precigen Reports Full Year 2023 Financial Results and Business Updates
- Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
- Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
- Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 252.42m |
Free float | 223.54m |
P/E (TTM) | -- |
Market cap | 353.39m USD |
EPS (TTM) | -0.3933 USD |
--
More ▼